科研学者

符立梧

职务:职代会常设委员会主任,抗癌药物研究室主任,伦理委员会副主任
职称:教授、博士生导师

教育背景
1993/9-1996/7    中山医科大学    肿瘤药理与化疗学    博士  全日制  
1990/9-1993/7    中山医科大学    毒理学                      硕士  全日制
1982/9-1987/7    广东医药学院    医学                         本科  全日制

工作经历
2020/7-至今           中山大学肿瘤防治中心                             职代会常设委员会主任
2006/6-2021/6       中山大学肿瘤防治中心                             实验研究部主任
2003/10-2006/10   中山大学肿瘤防治中心                             科研处处长
2002/6-至今           中山大学肿瘤防治中心                             教授(破格晋升),博士生导师
1999/1-2002/1       美国南卡医科大学(MUSC)                   博士后
1998/12-2002/5     中山大学(原中山医科大学)肿瘤中心    副研究员
1996/7-1998/11     中山医科大学                                            讲师
1987/7-1990/9       广东医药学院                                            助教

专业技术特长或学科方向
  专长于抗癌药物药理学、新型抗肿瘤药物的开发及实现肿瘤化疗个体化的研究。近年来主要从事肿瘤细胞抗药性的介导与逆转(尤其是多药抗药性)、肿瘤干细胞抗药性,建立了以肿瘤微组织块培养的肿瘤药敏试验系统,实现肿瘤化疗药物个体化的研究。

学术期刊任职情况
多年来,担任国内外20多家期刊编委,如:

Advances in Cancer Research and Therapy (2022-)
Basic and Clinical Pharmacy Research(2022.9-)
Drug Resistance Updates (2022.8-)
Frontiers in Oncology - Cancer Molecular Targets and Therapeutics (2022.3-)
Journal of Clinical and Translational Medicine (2021.10-)
Molecules(2021.10-)
Annals of Integrative Oncology (2021.3-)
American Journal of Clinical and Biomedical Research (2021.2-)
Cancer Drug Resistance (2020.11-)
Annals of Clinical Oncology (2018.8-)
International Journal of Cancer and Treatment(2018.5-)
Journal of Experimental Medicine and Biology (2018.3-)
Journal of Clinical Research(2017.07-)
Austin journal of cancer and clinical research(2016.1-)
International Journal of Clinical Pharmacology and Pharmacotherapy (2015.8-)
Journal of Biochemistry and Molecular Biology Research (2014.10-)
Acta Pharmaceutica Sinica B(2011.10-)
《国际肿瘤前沿杂志》 编委(2019.7-)
《中山大学学报》(医学科学版) 编委(2014.1 -)
《肿瘤药学》副主编(2013.01)
《中国药理学通报》编委(2013.1 -)
《中国新药杂志》编委(2009.3-)
《肿瘤研究与临床》编委(2008.10-)
《药学学报》编委(2008.10-)
《中华肿瘤防治》编委(2006.1-)
《中国临床药理学杂志》编委(2004.1-)
《现代诊断与治疗》特邀编委(2003.1-)

参加学术团体及任职情况
广东省卫健委第二届伦理委员会  专家组成员(2019-)
广东省抗癌协会抗肿瘤药理专业委员会  主任委员(创办者2016.11.5-)
广州市重大行政决策论证专家(2015-)
中国抗癌协会  理事(2012.9-2017.12)
广东省药理学会肿瘤药理专业委员会  主任委员(创办者2009.7-)(2015.12-荣誉主任委员)
中国抗癌协会抗癌药物委员会  副主任委员(2007.6-)
广东省药理学会  常务理事 (2005.10-)
中国药理学会肿瘤药理与化疗专业委员会  副主任委员(2004.6-)
美国癌症研究学会(AACR)  会员 (2004.6-)
中国FDA  咨询专家(2003-)
广东省FDA  咨询专家(2003-)

学术业绩
概况:

  符立梧,教授,博士生导师。华南恶性肿瘤防治全国重点实验室,中山大学肿瘤防治中心实验研究部主任(2006-2020),现任中山大学肿瘤防治中心(肿瘤医院)抗癌药物研究室主任,伦理委员会副主任、广东省卫健委伦理专家组成员(2019-2024),中国抗癌协会理事(2013-2017)、中国抗癌协会抗癌药物专业委员会副主任委员(2003-2017)、中国药理学会肿瘤药理专业委员会副主任委员(2003-2017),广东省药理学会常务理事,广东省药理学会肿瘤药理专业委员会创立者和荣誉主任委员(创立者:2010-2015),广东抗癌协会抗抗肿瘤药物专业委员会创立者和荣誉主任委员(创立者:2015-2019),国内外20多种学术期刊包括Mol Pharmacol、Am J Cancer Res、APSB等编委。主要从事肿瘤药理学研究和实现化疗药物个体化的研究,主要包括肿瘤多药耐药性的介导与逆转,发现抗癌药物可增加ABCB1/P-gp、野生型EGFR膜间转移,介导敏感的肿瘤细胞瞬时获得耐药表型。发现多种药物如粉防已碱、TKIs等均能体内外逆转MDR作用;发现ERK、STAT3信号和ALDH2与肿瘤局部免疫微环境有关;建立了以肿瘤微组织块培养的肿瘤药敏试验系统,实现化疗药物个体化。近年来做为课题负责人主持研究的省部级以上课题有:863项目、973课题、重大研发计划课题、国家自然科学基金面上项目10项(联合基金1项)等。发表论文290多篇,SCI收录论文250多篇其中包括Cancer Res(8篇 IF:13.3)、Mol Cancer(IF:41.4)、Adv Sci(IF:17.5)、STTT(IF:38.1)、Drug Resist Updat(IF:22.8)、Nat Commun(IF:17.6)、APSB(IF:14.9)等。获得专利10多项以及多个学术奖项。

一、发表论文著作情况
以下为近5年发表的代表性论文:
2022

1、Zhang Y#, Li C#, Xia C, Wah To KK, Guo Z, Ren C, Wen L, Wang F, Fu L*, Liao N*. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Cell Commun Signal. 2022 Sep 14;20(1):142.IF: 7.5
2、Fan Y#, Tao T#, Guo Z, Wah To KK, Chen D, Wu S, Yang C, Li J, Luo M, Wang F, Fu L*. Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo. Mol Ther Oncolytics. 2022 Feb 16;24:636-649. IF: 6.3
3、Fu L*, Chen ZS*. Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure. Signal Transduct Target Ther. 2022 Mar 17;7(1):89. IF: 38.1
4、Fan J, Bellon M, Ju M, Zhao L, Wei M, Fu L*, Nicot C*. Clinical significance of FBXW7 loss of function in human cancers. Mol Cancer. 2022 Mar 26;21(1):87.IF: 41.4
5、Zhao T, Wang X, Fu L*, Yang K*. Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response. Cancer Drug Resist. 2022 May 12;5(2):436-450.
6、Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022 Dec 8;15(1):173. IF: 23.1
7、Fan J, To KKW, Chen ZS, Fu L. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance. Drug Resist Updat. 2022 Nov 30;66:100905. IF: 22.8
2021
8、Rong QX#, Wang F#, Guo ZX, Hu Y, An SN, Luo M, Zhang H, Wu SC, Huang HQ*, Fu LW*. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma. Mol Cancer. 2021 May 29;20(1):80. IF: 41.4
9、Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L*. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. Mol Cancer. 2021 Jan 18;20(1):17. IF: 41.4
10、Zhang H#, Xia Y#, Wang F#, Luo M, Yang K, Liang S, An S, Wu S, Yang C, Chen D, Xu M, Cai M, To KKW, Fu L*. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. Adv Sci (Weinh). 2021 Mar 24;8(10):2003404. 
IF: 17.5
11、Yang C, Yang C, Yarden Y, To KKW, Fu L*. The prospects of tumor chemosensitivity testing at the single-cell level. Drug Resist Updat. 2021 Jan;54:100741. IF:22.8
12、Su C#, Zhang J#, Yarden Y, Fu L*. The key roles of cancer stem cell-derived extracellular vesicles. Signal Transduct Target Ther. 2021 Mar 8;6(1):109. IF: 38.1
13、Huang L, Guo Z, Wang F, Fu L*. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386.IF: 38.1
14、Luo M#, Xia Y#, Wang F, Zhang H, Su D, Su C, Yang C, Wu S, An S, Lin S*, Fu L*. PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. Acta Pharm Sin B. 2021 Oct;11(10):3120-3133.IF: 14.9
15、Zhang H, Fu L*. The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment. Acta Pharm Sin B. 2021 Jun;11(6):1400-1411. IF: 14.9
16、Yang K, Wang F, Zhang H, Wang X, Chen L, Su X, Wu X, Han Q, Chen Z, Chen ZS, Fu L*. Target Inhibition of CBP Induced Cell Senescence in BCR-ABL-T315I Mutant Chronic Myeloid Leukemia. Front Oncol. 2021 Jan 8;10:588641. IF: 5.7
17、Luo KW, Xia J, Cheng BH, Gao HC, Fu LW*, Luo XL*. Tea polyphenol EGCG inhibited colorectal-cancer-cell proliferation and migration via downregulation of STAT3. Gastroenterol Rep (Oxf). 2020; 9(1):59-70. IF: 4.0
2020
18、Luo M, Wang F, Zhang H, To KKW, Wu S, Chen Z, Liang S, Fu L*. Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. Signal Transduct Target Ther. 2020 Aug 28;5(1):141. IF: 38.1
19、Wang F, Qi XM, Wertz R, Mortensen M, Hagen C, Evans J, Sheinin Y, James M, Liu P, Tsai S, Thomas J, Mackinnon A, Dwinell M, Myers CR, Bartrons R, Fu L*, Chen G*. p38gamma MAPK is essential for aerobic glycolysis and pancreatic tumorigenesis. Cancer Res. 2020 Jun 24:3281. IF: 13.3
20、Wang X, Wang F, Zhong M, Yarden Y, Fu L*. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer. 2020 May 2;19(1):81. IF: 41.4
21、Zeng F#, Wang F#, Zheng Z#*, Chen Z, Wah To KK, Zhang H, Han Q, Fu L*. Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo. Acta Pharm Sin B. 2020 May;10(5):799-811. IF: 14.9
22、Wang F#, Li D#, Zheng Z, Kin Wah To K, Chen Z, Zhong M, Su X, Chen L*, Fu L*. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1. J Exp Clin Cancer Res. 2020 Mar 12;39(1):50. IF: 12.6
23、Liang SB#, Wang F#, Luo M, Zhang H, Wu SC, Chen Z, Fu LW*. PBA2, a novel compound, enhances radiosensitivity in various carcinoma cells by activating the p53 pathway in vitro and in vivo. Free Radic Biol Med. 2020 Oct 17;161:224-233. IF: 8.1
24、Fu L. Editorial of special issue on pharmacotherapeutics of digestive tumors. Gastroenterol Rep (Oxf). 2020 Jul 2;8(3):177-178. IF: 4.0
25、Zhong M, Fu L*. Culture and application of conditionally reprogrammed primary tumor cells. Gastroenterol Rep (Oxf). 2020 Jun 25;8(3):224-233. IF: 4.0
26、Zhang JY#, Yan YY#, Li JJ, Adhikari R, Fu LW*. PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. Front Pharmacol. 2020 May 15;11:722. IF: 5.9
27、Cui C#, Yang J#, Li X, Liu D, Fu L*, Wang X*. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. Mol Cancer. 2020 Mar 14;19(1):58. IF: 41.4
28、Luo KW, Xia J, Cheng BH, Gao HC, Fu LW*, Luo XL*. Tea polyphenol EGCG inhibited colorectal-cancer-cell proliferation and migration via downregulation of STAT3. Gastroenterol Rep (Oxf). 2020 Dec 3;9(1):59-70. IF: 4.0
29、Aslam S, Xi Y, Ahmad M, Mansha A*, Farooq T, Zheng ZH, Saddique Fa, Wang F, Fu LW*. Anticancer activity of structural hybrids of various 5/6-membered-heterocycles with pyrazolobenzothiazine 5,5-dioxide. Pakistan Journal of Pharmaceutical Sciences  2020 May;33(Sup):1239-1243 IF: 0.8
30、Yeh CH, Bellon M, Wang F, Zhang H, Fu L, Nicot C*. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Mol Cancer. 2020 Sep 9;19(1):139. IF: 41.4
2019
31、Wang X, Qiao D, Chen L, Xu M, Chen S, Huang L, Wang F, Chen Z, Cai J, Fu L*. Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance. Mol Cancer. 2019 Dec 12;18(1):182. IF: 41.4
32、Xu M, Wang F, Li G, Wang X, Fang X, Jin H, Chen Z, Zhang J, Fu L*. MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC. Mol Cancer. 2019 May 9;18(1):93. IF: 41.4
33、Zhang H, Huang L, Tao L, Zhang J, Wang F, Zhang X, Fu L*. Secalonic acid D induces cell apoptosis in both sensitive and ABCG2-overexpressing multidrug resistant cancer cells through upregulating c-Jun expression. Acta Pharm Sin B. 2019 May;9(3):516-525. IF: 14.9
34、Luo F#, Luo M#, Rong QX, Zhang H, Chen Z, Wang F, Zhao HY*, Fu LW*. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. J Immunother Cancer. 2019 Sep 11;7(1):245. IF: 12.4
35、Liang SB#, Zhang N#, Chen DM, Yang XL, Chen BH, Zhao H, Lu RL, Chen Y*, Fu LW*. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma. Radiother Oncol.  2019 Mar;132:223-229. IF: 6.9
36、Zhang Z#, Ma C#, Li P, Wu M, Ye S*, Fu L*, Xu J*. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediatedby ABCB1 and ABCG2 in vitro and in vivo. Cell Commun Signal. 2019 Sep 1;17(1):110. IF: 7.5
37、Aslam S, Wang F, Ahmad M, Zahoor AF, Mansha A*, Rasul A, Fu L*. Benzothiazine based acetohydrazides and acetamides as anticancer agents. Pak J Pharm Sci. 2019 Nov;32(6(Supplementary)):2795-2800. IF: 0.8
38、Cui C, Yang J, Fu L, Wang M, Wang X*. Progress in understanding mitochondrial calcium uniporter complex-mediated calcium signalling: A potential target for cancer treatment. Br J Pharmacol. 2019 May;176(9):1190-1205. IF: 9.4
39、Tan Y#, Lin JJ#, Yang X, Gou DM, Fu L, Li FR*, Yu XF*. A panel of three plasma microRNAs for colorectal cancer diagnosis. Cancer Epidemiol. 2019 Jun;60:67-76. IF: 2.8
40、Niu Y#, Su M#, Wu Y, Fu L, Kang K, Li Q, Li L, Hui G, Li F*, Gou D*. Circulating Plasma miRNAs as Potential Biomarkers of Non-Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling. Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):327-336. IF: 4.0
41、Sheng J, Yu Y, Wang X, Qian Y, Fu L, Zhao Y, Ma M*, Hu W*. Synthesis of Paclitaxel Side Chain via Multi-Component Reaction and Its Application to the Synthesis of Paclitaxel Analogues. Chinese Journal of Organic Chemistry. 2019, 39 (2): 377-389. IF: 5.5
42、Xu L#, Huang J#, Liu J#, Xi Y#, Zheng Z, To KKW, Chen Z, Wang F, Zhang Y*, Fu L*. CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2. Mol Ther Oncolytics. 2019; 16:100-110. IF: 6.3
2018
43、Luo XL, Deng C, Su XD, Wang F, Chen Z, Wu XP, Liang SB, Liu J*, Fu L*. Loss of MED12 induces tumor dormancy in human epithelial ovarian cancer via downregulation of EGFR. Cancer Res. 2018 Jul 1;78(13):3532-3543. IF: 13.3
44、Yang L, Li M, Wang F, Zhen C, Luo M, Fang X, Zhang H, Zhang J, Li Q*, Fu L*. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo. Cell Physiol Biochem. 2018 May 5;46(6):2487-2499. IF:5.5
45、Ge C, Wang F, Cui C, Su X, Wah To KK, Wang X, Zhang H, Song X*, Fu L*. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells. Cell Physiol Biochem. 2018 Aug 16;48(6):2302-2317. IF:5.5
46、Wu S, Fu L*. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018 Feb 19;17(1):25. IF: 41.4
47、Zhang Z#, Guo X#, To KKW#, Chen Z#, Fang X, Luo M, Ma C, Xu J, Yan S*, Fu L*. Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo.  Acta Pharm Sin B. 2018 Jul;8(4):563-574. IF: 14.9
48、Guo X#, To KKW#, Chen Z#, Wang X, Zhang J, Luo M, Wang F, Yan S*, Fu L*. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo. J Exp Clin Cancer Res. 2018 Feb 20;37(1):31. IF: 12.6
49、Fang X#, Xie H#, Luo M, Chen Z, Wang F, Li Q, Wang X, Ding J*, Fu L*. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis. Biochem Pharmacol. 2018 Feb 3;150:131-140. IF: 6.1
50、An S, Fu L*. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562. IF: 11.2
51、To KKW*, Fu LW*. CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance. Invest New Drugs. 2018 Feb;36(1):10-19. IF: 3.6
52、Cui C, Chang Y, Zhang X, Choi S, Tran H, Penmetsa KV, Viswanadha S, Fu L*, Pan Z*. Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma. Cancer Lett. 2018 Sep 28;432:169-179. IF: 9.7
53、Choi S#, Cui C#, Luo Y, Kim SH, Ko JK, Huo X, Ma J, Fu LW, Souza RF, Korichneva I, Pan Z*. Selective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1. FASEB J. 2018 Jan;32(1):404-416 IF: 5.8
54、Liu Z, Luo C, Yang W, Wang K, Hu C, Zou J, Zhu H, Fu L, Nie J*, Cheng C*. Increased Numb protein expression predicts poor clinical outcomes in esophageal squamous cell carcinoma patients. Cancer Biol Ther. 2018 Jan 2;19(1):34-41. IF: 4.8
55、Tsang CK, Chen M, Cheng X, Qi Y, Chen Y, Das I, Li X, Vallat B, Fu LW, Qian CN, Wang HY, White E, Burley SK, Zheng XFS*. SOD1 Phosphorylation by mTORC1 Couples Nutrient Sensing and Redox Regulation. Mol Cell. 2018 May 3;70(3):502-515. IF: 19.3
56、符立梧,克服ATP结合盒药物转运泵介导的肿瘤多药抗药性的研究进展,中山大学学报(医学版),2018; 39 (6): 801-810. IF:1.6

二、承担科研项目情况
以下为近5年承担的主要项目:

1、氮杂苯并[f]薁衍生物类抗肿瘤新药的临床前研究(广州市科创委No.SL2022B03J00203,2022.10-2025.12,100万)
2、抗肿瘤药物相关心血管损伤的防控及干预(国家重点研发No.2022YFE0209700,2023.1-2025.12,245万)
3、循环肿瘤细胞的类器官培养实现常见实体肿瘤化疗药物个体化的研究(国家自然科学基金
联合基金项目No.U21A20421,2022.1-2025.12,260万)
4、MED12缺失介导卵巢癌细胞免疫逃逸作用及其机制(国家自然科学基金面上项目No.82073882,2020.1-2023.1,56万)
5、Lithocarpins 类抗肝癌药物先导化合物的发掘及成药性评价    (广东省重点研发计划GDNRC [2020]042    ,2020.1-2022.12,70万)
6、CBP抑制剂开发为抗胃癌、直肠癌新药的研究(国家重点研发2018ZX09711002-003-011,2019.1-2021.12,150万)
7、原代肿瘤细胞培养及微组织块药敏体系研究和开发(广州市开发区领军人才项目No.CY2018-002,2018.6-2022.6, 200万)
8、化疗药物促进外泌体介导的ABCB1细胞间转移作用及其机制(国家自然科学基金面上项目No.81673463,2017.1-2020.12,70万)

三、获奖与专利情况
多年来,获得以下多个奖项:

1、2022年医学领域全球顶尖前10万科学家排名发布(33883/10万)
2、2022年Elservier 发布2021“中国高被引学者”(Highly cited Chinese researchers)榜单上榜(医学领域67/608)
3、2021年全球学者库全国药学专家学术影响力百强排名(2021年7月)(46/100)(2021)
4、2021年Elservier 发布2020“中国高被引学者”(Highly cited Chinese researchers)榜单上榜
5、第一批广东省医学领军人才(2018)
6、广东省特支计划领军人才(2015)
7、符立梧,梁永钜,石智,戴春岭,闫燕艳   克服ABC转运泵介导的肿瘤多药抗药性的研究-2012年获广东省科技进步一等奖 (第一完成人)
8、符立梧,梁永钜,石智,戴春岭,闫燕艳,陈黎明 克服ABC转运泵介导的肿瘤多药抗药性的研究-2011年度中国抗癌协会科技进步一等奖K-1101-1-1 (第一完成人)(2012)
9、符立梧,梁永钜,石智,戴春岭,闫燕艳,潘启超,克服ABC药物转运泵介导的肿瘤多药抗药性的研究-2011年度高等学校科学研究优秀成果奖(自然科学奖)二等奖(第一完成人)(2011)
10、符立梧,梁永钜,石智,戴春岭,闫燕艳等  ABC转运泵与TKIs交互作用的研究-2012年中华医学科技进步三等奖(第一完成人)(2012)
11、符立梧,获第十一届广东省丁颖科技奖(2011)
12、“逆转肿瘤多药抗药性的系列研究” 卫生部科技进步三等奖 (1999)第1完成人
13、“逆转肿瘤多药抗药性的系列研究” 广东省科技进步三等奖(1999)第1完成人
14、“逆转肿瘤多药抗药性的系列研究”广东省医药卫生科技进步二等奖(1999)第1 完成人
15、“肿瘤MDR逆转及其机理”教育部科技进步三等奖(1999)第2完成人
16、卫生部青年科技优秀人才称号 (1998)
17、“番荔枝内酯克服MDR作用及机理”第三届中国新医药技术博士论坛优秀论文三等奖(1998)
18、首届中国药理学会-Servier优秀青年药理学工作者奖 (1997)

专利10多项,主要有:
1、夏承来、尹双红、蔡艳桃、王芳、 符立梧;甲酰胺衍生物CP068在制备抗肿瘤药物中的应用,申请号:CN202110949140.3
2、符立梧、凌晨、高艳锋;虚拟筛选的化合物在制备抗肿瘤药物中的应用及其药物,申请号:CN202011190390.5
3、钱宇、胡吉迪、尹鑫茹、许爱民、杨晓涵、符立梧、徐新芳、胡文浩;一种吲哚类衍生物及其制备方法和应用,申请号:CN202011134446.5
4、符立梧、王仁友;一种传染源隔离装置及隔离方法(发明专利), 申请号:CN202010086618.X
5、符立梧、王仁友;一种传染源隔离装置(实用新型), 申请号:CN202020161083.3 
6、符立梧、梁永钜;一种用于组织细胞活性检测仪的装置(实用新型),申请号:CN201620114694.6
7、符立梧、梁永钜、王仁友;肿瘤活组织体外培养系统及培养方法,申请号:CN201410212174.4
8、贺红武、符立梧、莫文妍、梁永钜;具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-D]嘧啶衍生物及制备,申请号:CN200910062289.9
9、符立梧、贺红武、梁永钜、莫文妍;具有抗肿瘤活性的2,3,4,7,8-多取代吡啶并[4,3-d]嘧啶衍生物,申请号:CN200910060650.4 
10、符立梧、阮继武、古练权;2,4,5-三取代咪唑类化合物及其合成方法和用于逆转肿瘤多药抗药性的作用,授权号:CN2002149752.4

 

更新时间:2023年2月10日